Psychotomimesis Mediated by κ Opiate Receptors
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The κ opioid agonists are analgesics that seem to be free of undesired morphine-like effects. Their dysphoric actions observed with the κ agonist cyclazocine are thought to be mediated by an action at σ-phencyclidine receptors. The benzomorphan κ agonist MR 2033 is inactive at σ-phencyclidine receptors. In male subjects, the opiate-active (-)-isomer, but not the (+)-isomer, elicited dose-dependent dysphoric and psychotomimetic effects that were antagonized by naloxone. Thus, κ opiate receptors seem to mediate psychotomimetic effects. In view of the euphorigenic properties of μ agonists, our results imply the existence of opposed opioid systems affecting emotional and perceptual experiences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“agonism of κ-opioid receptors were shown to produce depression-like symptoms in humans (Pfeiffer et al., 1986).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Pfeiffer et al., 1986
In the citing paper
“Nonetheless, the three receptor types have different behavioral domains, with MOR and DOR mediating generally positive motivation and affect, while KOR mediates generally negative motivation and aversion (Pfeiffer et al 1986; Shippenberg et al 1987; Pecina and Berridge 2000; McLaughlin et al 2003; for reviews see Van Ree et al 2000; Le Merrer et al 2009).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Pfeiffer et al 1986
In the citing paper
“Kappa receptor agonists induce anxiogenic and dysphoric effects in humans (141-143) and depressive-like behavior in animals (i.e., increased immobility in the forced swim test) (144, 145).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [141]
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 748
Martin, W. R. (1983) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06637-2 · Cited by 648
Thrills in response to music and other stimuli
Goldstein, A. (1980) · Physiological Psychology · doi:10.3758/bf03326460 · Cited by 522
Mucha, R. F., & Herz, A. (1985) · Psychopharmacology · doi:10.1007/bf00432213 · Cited by 510
Self-citationThe binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00495865 · Cited by 509
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Opiate receptor binding sites in human brain
Pfeiffer, A., Pasi, A., Mehraein, P., & Herz, A. (1982) · Brain Research · doi:10.1016/0006-8993(82)91150-7 · Cited by 298
Self-citationPhencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film.
Quirion, R., Hammer, R. P., Herkenham, M., & Pert, C. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5881 · Cited by 254
Research works printed but not linked: 6
- Jasinski, D. R., Drug Addiction 1: 216 (1977).
- MARTIN, W.R., PHARMACOL REV 35: 283 (1984).
- MARTIN, W.R., SUBSTANCE AND ALCOHOL ACTIONS/MISUSE 1: 269 (1980).
- Shearman, G. T., Drug Discrimination: Application in CNS Pharmacology: 37 (1982).
- VAUPEL, D.B., FAILURE OF NALTREXONE (NTX) TO ANTAGONIZE PHENCYCLIDINE (PCP) AND THE OPIOID SKF-10047 (SKF) IN THE DOG, FEDERATION PROCEEDINGS 41: 1333 (1982).
- Zerssen, D. V., Assessment of Depression: 270 (1985).
Cited by
Items 701–800 of 956
Opiate Receptors: Opioid Agonist‐Antagonist Effects
GOLDSTEIN, D. J., & Meador‐Woodruff, J. H. (1991) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1991.tb02613.x · Cited by 5
Risikobewertung von Pflanzen und pflanzlichen Zubereitungen
Klenow, S., & Risikobewertung, B. F. (2012) · OpenAgrar · doi:10.4126/98-004600308 · Cited by 5
Opiates, Opioids and Their Receptors in the Modulation of Pain
Herz, A. (1987) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-7091-6975-9_5 · Cited by 5
Self-citationReid, A. A., Kim, C.-H., Thurkauf, A., Monn, J. A., Costa, B. D., Jacobson, A. E., Rice, K. C., Bowen, W. D., & Rothman, R. B. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90111-4 · Cited by 5
Kappa Opioid Receptors Control a Stress-Sensitive Brain Circuit and Drive Cocaine Seeking
Damonte, V. M., Bailey, L. G., Thakar, A., Stralka, J., Brown, T. E., & Kauer, J. A. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.1233-25.2025 · Cited by 4
Bland, K., Chen, C., Huang, P., Ho, C. K., Howe, T., Ocampo, K., Zhao, P., Creed, S. M., Noel-Torres, J., Riley, A. P., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110316 · Cited by 4
G Protein Inactivation as a Mechanism for Addiction Treatment
Neiswanger, C., Ruiz, M. V., Kimball, K., Lee, C. J., Land, B. B., Berndt, A., & Chavkin, C. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.03.021 · Cited by 4
Bidirectional Modification of a Galbulimima Alkaloid Identifies Selective Opioid Ligands
Zielke, F. M., Woo, S., Kasmali, S., Volf, A., Dang, V. Q., Bailey, J., Gembický, M., Bohn, L., & Shenvi, R. A. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00573 · Cited by 4
Owens, F., Carbajal, C., Rodriguez, M., & El‐Hage, N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.028 · Cited by 4
Volf, A., Brust, T. F., Kobylski, R. R., Czekner, K. M., Stahl, E. L., Cameron, M. D., Trojniak, A. E., Wood, A. B., Aubé, J., & Bohn, L. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02372-8 · Cited by 4
Nosova, O., Bazov, I., Karpyak, V. M., Hallberg, M., & Bakalkin, G. Y. (2021) · Molecules · doi:10.3390/molecules26113458 · Cited by 4
Co-Administration of nalbuphine to improve morphine tolerance in mice with bone cancer pain
Ren, B., Zhang, J., Yang, X., Sun, D., Sheng, D., Fang, Q., & Ji, Z. (2023) · Molecular Pain · doi:10.1177/17448069231178741 · Cited by 4
Tran, L. T., Freeman, K. T., Lunzer, M. M., Portoghese, P. S., & Haskell‐Luevano, C. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00604 · Cited by 4
Boecker, H., Tölle, T. R., Valet, M., & Sprenger, T. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3293-7_22 · Cited by 4
Abbadie, C., & Pasternak, G. W. (2002) · Handbook of chemical neuroanatomy · doi:10.1016/s0924-8196(02)80003-3 · Cited by 4
Kappa Opioids: Problems and Opportunities in Analgesia
Butelman, E. R., & Kreek, M. J. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch013 · Cited by 4
Opposing Tonically Active Endogenous Opioid System Modulating the Mesolimbic Dopamine Reward Pathway
Herz, A. (1995) · Springer eBooks · doi:10.1007/978-3-7091-6901-8_1 · Cited by 4
Self-citationOpioid Peptide-Derived Analgesics
Schiller, P. W. (2008) · Springer eBooks · doi:10.1007/978-0-387-76678-2_22 · Cited by 4
AbdelMagid, M. E., & Gajewski, J. B. (1997) · Urology · doi:10.1016/s0090-4295(97)00086-1 · Cited by 4
Chen, C., Yin, J., Li, J.-G., Xue, J.-C., Weerawarna, S. A., Nelson, W. L., & Liu‐Chen, L. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00560-2 · Cited by 4
Psychiatric Aspects of Opioid Research
Emrich, H. M., & Schmauss, C. (1991) · Springer eBooks · doi:10.1007/978-3-642-46660-1_22 · Cited by 4
Self-citationRuan, X., Hall, S. M., & Kaye, A. D. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.05.007 · Cited by 4
Exploring the Aversive and Anxiogenic Effects of Novel Kappa Opioid Receptor Agonists in Rats
Culverhouse, A. (2016) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17014082 · Cited by 4
Endogenous Opioid Systems in the Control of Pain
Millan, M. J., Weihe, E., & Członkowski, A. (1991) · Springer eBooks · doi:10.1007/978-3-642-46660-1_15 · Cited by 4
Gao, Y., Zhu, H., Lv, L., Xu, X., Li, W., & Fu, W. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116643 · Cited by 3
Kappa opioid receptor mediated operant performance in male and female rats
Namchuk, A. B., Tsuda, M. C., Lucki, I., & Browne, C. A. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173847 · Cited by 3
Hammond, H. R., Chaudhari, P., Bunnell, A., Nefzi, K., Chen, C., Zhao, P., Eans, S. O., Masood, S. R., Dooley, C. T., Liu‐Chen, L., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00333 · Cited by 3
Anand, J. P., Porter‐Barrus, V. R., Waldschmidt, H. V., Yeomans, L., Pogozheva, I. D., Traynor, J. R., & Mosberg, H. I. (2013) · Biopolymers · doi:10.1002/bip.22437 · Cited by 3
Cannabinoid-Opioid Interactions
Miller, M. L., Chadwick, B. J., Morris, C. V., Michaelides, M., & Hurd, Y. L. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2294-9_15 · Cited by 3
The Widely Available Hallucinogenic Plant Salvia divinorum and Its Main Component, Salvinorin A
Butelman, E. R., & Kreek, M. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00069-8 · Cited by 3
Şenormancı, G., Turan, Ç., Çelik, S., Çelik, A., Edgünlü, T., Akbaş, D., Akça, A. S. D., & Şenormancı, Ö. (2020) · Journal of Ethnicity in Substance Abuse · doi:10.1080/15332640.2020.1785361 · Cited by 3
Ruan, X., Bumgarner, G. W., & Kaye, A. D. (2016) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000382 · Cited by 3
The contribution of serotonin 1A receptors to kappa opioid immunosuppression
Чейдо, М. А., & Idova, G. V. (2009) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-009-9169-8 · Cited by 3
Bremner, J. D., & Vermetten, E. H. G. J. M. (2007) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615377503.lg12 · Cited by 3
Sánchez, M., & Miquel (2003) · Repositori digital de la UPF (Universitat Pompeu Fabra) · Cited by 3
Opioid and non-opioid activities of the dynorphins
Marinova, Z. (2005) · Figshare · Cited by 3
Assessing spiradoline-like discriminative effects of DuP 747: Influence of route of administration
Holtzman, S. G., Steinfels, G. F., & Schmidt, W. K. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90148-1 · Cited by 3
Design and Synthesis of Novel Linear and Cyclic Peptide Ligands for Kappa Opioid Receptors
Fang, W. (2008) · KU ScholarWorks (The University of Kansas) · Cited by 3
Psychotomimetic Effects of Opioids
Pfeiffer, A. F. H. (1991) · Springer eBooks · doi:10.1007/978-3-642-46660-1_21 · Cited by 3
Self-citationEwald, A. W. M. (2016) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17148113 · Cited by 3
Butelman, E. R., & Kreek, M. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00285 · Cited by 3
Genetic Analysis of the Endogenous Opioid System
Pintar, J. E., & Kieffer, B. L. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18934-0_11 · Cited by 3
Huang, P., Ho, C. K., Bland, K., & Liu‐Chen, L. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138154 · Cited by 2
Nalfurafine is Aversive at Antinociceptive Doses in Mice
Kuijer, E. J., Marinelli, L. H., Bailey, S., Heal, D. J., Smith, S. L., Wonnacott, S., & Bailey, C. P. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70201 · Cited by 2
Addictive drug abuse and depression-a focus on epigenetics
Zhang, W., Xu, M., Wang, C., Liang, H., Zhu, X., Pan, Y., & Guo, F. (2026) · Communications Biology · doi:10.1038/s42003-026-09705-9 · Cited by 2
Ganado, M., Rubio, C., Pérez-Villavicencio, J., Serrano, N., Parra, H. R., Lee, Á., & Rubio‐Osornio, M. (2026) · Biomedicines · doi:10.3390/biomedicines14020476 · Cited by 2
Structural dynamics of kappa opioid receptor interactions with β-arrestin 1
Han, J., Fine, E. J., Jiang, Q., Zhuang, Y., Suomivuori, C., Chen, Z.-W., Denn, E., Whiddon, K., Li, K., Evers, A. S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73968-3 · Cited by 2
Frameworks of Alcohol Addiction
Koob, G. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405941-2.00001-8 · Cited by 2
Neurochemical Adaptations and Cocaine Dependence
Cosgrove, K., & Staley, J. K. (2007) · CRC Press eBooks · doi:10.1201/9781420054422.ch5 · Cited by 2
Fang, W., Bennett, M. A., Murray, T. F., & Aldrich, J. V. (2010) · Biopolymers · doi:10.1002/bip.21495 · Cited by 2
Burke, N. N., Li, Y., Deaver, D. R., Finn, D. P., Roche, M., Eyerman, D. J., Sánchez, C., & Kelly, J. P. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119872203 · Cited by 2
Benowitz, N. L., & Zevin, S. (2007) · CRC Press eBooks · doi:10.1201/9781420054446.ch8 · Cited by 2
Behavioral Pharmacology of Opiates
Zacny, J. P., & Walker, E. A. (1998) · Springer eBooks · doi:10.1007/978-1-4757-2913-9_24 · Cited by 2
Persönlichkeits- und Impulskontrollstörungen — Neurobiologie
Schmahl, C. G., & Bohus, M. (2006) · Springer eBooks · doi:10.1007/3-540-30887-3_15 · Cited by 2
Medical Complications of Drug Abuse
Benowitz, N. L. (2006) · CRC Press eBooks · doi:10.1201/9781420003468.ch8 · Cited by 2
Enhancement of Opioid Antinociception by Nicotinic Ligands
de Moura, F. B., & Bergman, J. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000423 · Cited by 2
Kaya-Akyüzlü, D., Özkan-Kotiloğlu, S., Şahiner, Ş. Y., ERTAN, E. A., & İlhan, İ. Ö. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174862 · Cited by 2
On antidepressant effects of running and SSRI : Focus on hippocampus and striatal dopamine pathways
Bjørnebekk, A. (2007) · Figshare · Cited by 2
Chakrama, F. Z. (2011) · theses.fr (ABES) · doi:10.70675/0af95636z489fz4fa9za54fz4cc1a23ada02 · Cited by 2
The effect of novel kappa opioid peptide receptor agonists on learning and memory in rats
Welsh, S. A. (2017) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17065427 · Cited by 2
Genes, neurocognition, and HIV risk behaviors in the context of methamphetamine and HIV
Bousman, C. (2009) · eScholarship (California Digital Library) · Cited by 2
Dykstra, L. A. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-60963-3_5 · Cited by 2
Bosch, P. (2013) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.22756706 · Cited by 2
An endogenous opioid alters neuronal plasticity to constrain cognitive flexibility
Olusakin, J., & Lobo, M. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02204-x · Cited by 2
Differential effects of endocannabinoid catabolic inhibitors on opioid withdrawal in mice
Gamage, T. F. (2013) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/xt10-c161 · Cited by 2
Neuropeptide Receptors: Novel Therapeutic Targets for Depression and Anxiety Disorders
Chaki, S., & Kanuma, K. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00300 · Cited by 1
A dynorphin theory of depression and bipolar disorder
Rappoport, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-44-345008-2.00010-2 · Cited by 1
The Potential Clinical Use of Opioid-Receptor-Modulating Drugs in Bipolar Disorder
Gefke, M., Wagner, C. B., McIntyre, R. S., & Vinberg, M. (2025) · CNS Drugs · doi:10.1007/s40263-025-01247-8 · Cited by 1
Holguin, G., & Martin‐Fardon, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1729040 · Cited by 1
Kappa opioid receptor antagonism in neuropsychiatry: from molecular mechanisms to clinical prospects
Wang, H., Ji, Y., Huang, J., Yang, S., Zhang, Q., Hu, S., Xu, X., & Yang, C. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-026-02216-y · Cited by 1
Burek, D., & Carlezon, W. A. (2026) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2026.07.009 · Cited by 1
Liu, A., Liu, P.-W., Luo, J.-W., Yao, S.-Y., Wang, B.-Y., Wang, C.-Y., Ye, R.-F., Zan, G., Sun, M., Liu, J. J., et al. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02549-1 · Cited by 1
The Pharmacokinetics of Preventive Acetaminophen
Yap, A. J. C. Y. (2016) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000378 · Cited by 1
Bouchard, N. C., & Nelson, L. S. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1367-1.00184-1 · Cited by 1
Genetic Studies of Opioid System Function in Mice
Ansonoff, M. A., Wen, T., & Pintar, J. E. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-993-2_13 · Cited by 1
Towards a pharmacology of depersonalization
Sierra, M. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511730023.009 · Cited by 1
Carsten, K., & Selena, E. (2012) · InTech eBooks · doi:10.5772/32239 · Cited by 1
Staley, J. K., & Cosgrove, K. (2006) · CRC Press eBooks · doi:10.1201/9781420003468.ch6 · Cited by 1
Motivating Change in Addiction via Modulation of the Dark Side
Koob, G. F. (2018) · Nebraska Symposium on Motivation/The Nebraska symposium on motivation · doi:10.1007/978-3-319-96920-6_1 · Cited by 1
Ätiopathogenese und Neurobiologie
Priebe, K., Schmahl, C. G., & Stiglmayr, C. (2013) · Springer eBooks · doi:10.1007/978-3-642-35066-5_4 · Cited by 1
Interactive effects of (±)-trans-U50488 and its stereoisomers with cannabinoids
Erwin, L. L., Nilges, M. R., Denys, I. B., Sutphen, J. C., Friend, A. J., Kapusta, D. R., & Winsauer, P. J. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173218 · Cited by 1
Schmahl, C. G. (2009) · Springer eBooks · doi:10.1007/978-3-540-88489-7_4 · Cited by 1
Nava-Gomez, L. J., & González-González, J. C. (2022) · Revista Iberoamericana ConCiencia. · doi:10.32654/concienciaepg/eds.especial-9 · Cited by 1
Scott, C. E., Pickering, E. V., & Anderson, G. T. (2022) · ACS symposium series · doi:10.1021/bk-2022-1428.ch007 · Cited by 1
Silva, M. J., Coffee, Z. H., Yu, C. H., & Hu, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041354 · Cited by 1
Luca, G. P. D., Anibaldi, G., Paolucci, D., Motta, P., & Persis, S. D. (2024) · Heroin addiction and related clinical problems · doi:10.62401/2531-4122-2024-7 · Cited by 1
Flores‐Ramirez, F. J., Illenberger, J. M., & Martin‐Fardon, R. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100695 · Cited by 1
A single compound alternative to a buprenorphine/naltrexone combination
Ridzwan, I. E. (2012) · The University of Bath Online Publications Store (The University of Bath) · Cited by 1
Friderichs, E., Christoph, T., & Buschmann, H. (2011) · Wiley eBooks · doi:10.1002/14356007.o02_o10 · Cited by 1
Factors Influencing Opioid Receptor Signaling to Adenylyl Cyclase.
Levitt, E. S. (2010) · Deep Blue (University of Michigan) · Cited by 1
Cocaine effects on striatal dynorphin and CART neuropeptides : Association to mood disorder
Fagergren, P. (2003) · Figshare · Cited by 1
Investigation of Natural Product Scaffolds for the Development of Opioid Receptor Ligands
Smith, K. M. (2012) · KU ScholarWorks (The University of Kansas) · Cited by 1
Lefever, M. R. (2010) · UA Campus Repository (The University of Arizona) · Cited by 1
Pharmacotherapies for Treatment of Opioid Dependence
Vocci, F. J., & Sorer, H. (1992) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2010.0165 · Cited by 1
Kumor, K. M., Clark, W. C., Janal, M. N., & Haertzen, C. A. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90176-i · Cited by 1
The role of dopamine in the effects of pentazocine and tripelennamine
Hudzik, T. J., & Slifer, B. L. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90254-f · Cited by 1
Multiple opioide Systeme: Klinische Aspekte
Pfeiffer, A. F. H. (1987) · Verhandlungen der Deutschen Gesellschaft für Innere Medizin · doi:10.1007/978-3-642-85460-6_98 · Cited by 1
Self-citationShippenberg, T. S. (1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3_19 · Cited by 1
Studies on Ligands of the Kappa Opioid Receptor
DiMattio, K. M. (2016) · TUScholarShare (Temple University) · Cited by 1
Neural mechanisms of MK-801 induced sensitisation
Lefevre, E. M. (2016) · The University of Queensland · doi:10.14264/uql.2016.911 · Cited by 1
Metadata
- Authors
- Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M.
- Affiliations
- LMU Klinikum (DE)
- Boehringer Ingelheim (Germany) (DE)
- Max Planck Society (DE)
- Max Planck Institute of Psychiatry (DE)
- ORCID
- Pfeiffer, Andreas
- Venue
- Science
- Published
- 1986-08-15
- Volume
- 233
- Issue
- 4765
- Pages
- 774-776
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2032643119
- Cited by
- 857
- References
- 30
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 23 · 2023: 17 · 2022: 18 · 2021: 38 · 2020: 42 · 2019: 21 · 2018: 27 · 2017: 24 · 2016: 37 · 2015: 38 · 2014: 30 · 2013: 35 · 2012: 41
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psychotomimetic effects, kappa opioid receptor, kappa opioid receptor agonists, cyclazocine, naloxone antagonism, stereoisomers, mu-opioid receptor agonists, euphoria, analgesia
- MeSH terms
- Adult, Anxiety, Benzomorphans, Humans, Male, Middle Aged, Morphinans, Naloxone, Personality Tests, Phencyclidine, Receptors, Opioid, Receptors, Opioid, kappa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.